

TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED

CONSOLIDATED AUDITED QUARTERLY RESULTS FOR THE QUARTER ENDED MARCH, 2014



Particulars	3 Months ended 31-03-2014	Preceeding 3 months ended 31-12-2013	Corresponding 3 months ended 31-03-2013	Year to date figures for the current period ended 31-03-2014	Year ended 31-03-2013
	Audited	Unaudited	Audited	Audited	Audited
1. Net Sales / Income from Operations	139.63	109.61	124.82	484.75	516.82
2. Other Income	13.47	27.20	0.62	91.13	79.47
3. Total Income	153.10	136.81	125.44	575.88	596.30
4. Expenditure					
a. (Increase)/Decrease in stock in trade and work in Progress	20.71	(5.01)	16.10	1.07	27.19
b. Consumption of Raw Material		Nil			Nil
c. Purchase of Traded Goods	98.31	104.73	77.73	422.95	427.96
d. Employees Cost	14.39	9.37	9.14	33.13	25.93
e. Rent	1.50	1.50	1.86	6.00	6.99
f. Depreciation	7.18	7.55	6.48	28.53	26.63
g. Other Expenditure	7.84	4.45	11.13	22.62	26.17
Total	149.93	122.58	122.44	514.30	540.87
5. Interest	0.13	0.15	0.70	0.64	0.70
6. Exceptional items	Nil	Nil	Nil	Nil	Nil
7. Profit/ (Loss) from Ordinary activities before tax (3) - (4+5+6)	3.04	14.08	2.30	60.94	54.72
8. Tax Expense (Including Deferred Tax)	(0.54)	4.54	0.00	19.36	16.99
9. Net Profit/ (Loss) from Ordinary activities after Tax (7-8)	3.58	9.54	2.30	41.58	37.74
10. Extraordinary Items	Nil	Nil	Nil	Nil	Nil
11. Net Profit/ (Loss) for the period (9-10)	3.58	9.54	2.30	41.58	37.74
Paid-up Equity Share Capital (Face Value of					
12. Rs.10/- each)	810.00	810.00	810.00	810.00	810.00
13. Reserves excluding revaluation reserves as per balance sheet of previous accounting year	293.26	293.26	134.02	293.26	134.02
14. Earnings Per Share (EPS)					
a. Basic and diluted EPS before extraordinary items for the period, for the year to date and for the previous year (not to be annualised)	0.05*	0.14	0.03*	0.60	0.55
15. Public Share Holding					
- Number of Shares	3166200	3366200	3366200	3166200	3366200
- Percentage of shareholding	39.09%	41.56%	41.56%	39.09%	41.56%
16. Promoters and promoter group shareholding					
a. Pledged / encumbered					
- No of Equity Shares	Nil	Nil	Nil	Nil	Nil
- Percentage of Shares (of the shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil	Nil
- Percentage of Shares (of the total share capital of the company)	Nil	Nil	Nil	Nil	Nil
a. Non encumbered					
- No of Equity Shares	4933800	4733800	4733800	4933800	4733800
- Percentage of Shares (of the shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%
- Percentage of Shares (of the total share capital of the company)	60.91%	58.44%	58.44%	60.91%	58.44%

* Weighted Average Number of Equity Shares considered



Trimurthi Drugs & Pharmaceuticals Ltd.


4-4-231/1/2 ABC, Inder Bagh, Sultan Bazar,

Hyderabad - 500 095, A.P., India

T: 040 2455 370

W: www.trimurthigroup.com

TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED
CONSOLIDATED AUDITED QUARTERLY RESULTS FOR THE QUARTER ENDED MARCH, 2014



TRIMURTHI
GROUP

Segment Reporting

	Particulars	Quarters ended			Year ended	Year ended
		31/03/2014	31/12/2013	31/03/2013	31/03/2014	31/03/2013
		Audited	Unaudited	Audited	Audited	Audited
1.	Segment Revenue					
	a. Pharma Business	133.27	113.01	106.63	486.39	525.25
	b. Financial Services	19.83	23.79	18.81	89.48	70.75
	c. Investments	0.00	0.01	0.00	0.01	50.80
	d. Trading in Shares	0.00	0.00	0.00	0.00	0.00
	Total	153.10	136.81	125.44	575.88	646.80
2.	Segment Profits					
	a. Pharma Business	(13.32)	(14.49)	(14.49)	(19.51)	(9.50)
	b. Financial Services	16.36	16.79	16.79	80.44	63.93
	c. Investment	0.00	0.00	0.00	0.01	0.29
	d. Trading in Shares	0.00	0.00	0.00	0.00	0.00
	Total	3.04	2.30	2.30	60.94	54.72
3.	Capital Employed					
	a. Pharma Business	413.38	380.76	299.55	413.38	380.76
	b. Financial Services	681.82	664.88	409.82	681.82	664.88
	c. Investments	31.50	2.00	50.54	31.50	2.00
	d. Trading in Shares	0.00	Nil	0.00	0.00	Nil
	Total	1126.70	1047.64	759.91	1126.70	1047.64

Notes:

1. The above results have been reviewed by Audit Committee and approved by the board of directors of the company at their meeting held on 24-05-2014.
2. During the Quarter under review the Company has acquired 2,95,000 Equity Shares of Rs. 10/- each of M/s Trimurthi Pharmaceuticals (India) Private Limited representing 59% of its Capital thereby making it as a Subsidiary.
3. The financial results for the quarter ended 31-03-2014 have been reviewed by the statutory auditors in pursuance of listing agreement.
4. (a) In segment reporting common assets that are used interchangeable not allocated to the individual segment above.
 (b) Previous Period Figures have been regrouped wherever necessary.
5. Figures of last quarter ended on 31-03-2014 are the balancing figures between audited figures in respect of the full financial year ended on 31-03-2014 and the published year to date figures upto the third quarter ended on 31-12-2013 of the current financial year.
6. The status of investor grievances for the quarter ended 31/03/2014:
 - a. pending at the beginning - Nil
 - b. received - 1
 - c. settled - 1
 - d. pending at the end - Nil

Place : Hyderabad,
Date :



Trimurthi Drugs & Pharmaceuticals Ltd.

4-4-231/1/2 ABC, Inder Bagh, Sultan Bazar,

Hyderabad - 500 095, A.P., India

T: 040 2475 7370

W: www.trimurthigroup.com

TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED
CONSOLIDATED ASSETS AND LIABILITIES FOR THE HALF YEAR ENDED ON 31-03-2014



TRIMURTHI
(Rupees in Lacs)

Particulars	As at 31/03/2014	As at 31/03/2013
A. EQUITY AND LIABILITIES		
1. Share Holders' Funds:		
(a) Share Capital	810.00	810.00
(b) Reserves and Surplus	334.84	293.26
(c) Money received against warrants		0.00
Sub-Total Share Holders' Funds	1144.84	1103.26
2. Share Application pending for Allotment	-Nil-	-Nil-
3. Minority Interest*	20.50	-Nil-
4. Non Current Liabilities:		
(a) Long Term Borrowings	1.36	4.38
(b) Deferred Tax Liabilities (Net)	11.60	13.70
(c) Other Long Term Liabilities	-Nil-	-Nil-
(d) Long Term Provisions	-Nil-	-Nil-
Sub-Total Non Current Liabilities	12.96	18.08
5. Current Liabilities		
(a) Short Term Borrowings	-Nil-	-Nil-
(b) Trade Payables	4.51	2.20
(c) Other Current Liabilities	12.32	11.08
(d) Short Term Provisions	22.29	19.58
(e) Inter Division	-Nil-	-Nil-
Sub-Total Current Liabilities	39.12	32.86
TOTAL EQUITY & LIABILITIES	1217.42	1154.20
B. ASSETS		
1. Non-Current Assets:		
(a) Fixed Assets	117.15	121.82
(b) Non-Current Investments	5.00	2.00
(c) Deferred Tax Assets (Net)	-Nil-	-Nil-
(d) Long Term Loans and Advances	20.52	21.78
(e) Other Non-Current Assets	2.69	12.21
Sub-Total Non Current Assets	145.36	157.81
2. Current Assets:		
(a) Current Investments	-Nil-	-Nil-
(b) Inventories	32.21	33.28
(c) Trade Receivables	84.72	81.64
(d) Cash & Cash Equivalents	132.84	36.90
(e) Short Term Loans and Advances	806.69	822.74
(f) Other Current Assets	15.60	21.83
Sub-Total Current Assets	1072.06	996.39
TOTAL ASSETS	1217.42	1154.20

Trimurthi Drugs & Pharmaceuticals Ltd.

4-4-231/1/2 ABC, Inder Bagh, Sultan Bazar,
 Hyderabad - 500 095, A.P., India

T: 040 2475 7370

W: www.trimurthigroup.com



TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED
AUDITED QUARTERLY RESULTS FOR THE QUARTER ENDED MARCH, 2014



TRIMURTHI
(Rs. In Lakhs)

Particulars	3 Months ended 31-03-2014	Preceeding 3 months ended 31-12-2013	Corresponding 3 months ended 31-03-2013	Year to date figures for the current period ended 31-03-2014	Year ended 31-03-2013
	Audited	Unaudited	Audited	Audited	Audited
1. Net Sales / Income from Operations	139.63	109.61	124.82	484.75	516.82
2. Other Income	13.47	27.20	0.62	91.13	79.47
3. Total Income	153.10	136.81	125.44	575.88	596.30
4. Expenditure					
a. (Increase)/Decrease in stock in trade and work in Progress	20.71	(5.01)	16.10	1.07	27.19
b. Consumption of Raw Material		Nil			Nil
c. Purchase of Traded Goods	98.31	104.73	77.73	422.95	427.96
d. Employees Cost	14.39	9.37	9.14	33.13	25.93
e. Rent	1.50	1.50	1.86	6.00	6.99
f. Depreciation	7.18	7.55	6.48	28.53	26.63
g. Other Expenditure	7.84	4.45	11.13	22.62	26.17
Total	149.93	122.58	122.44	514.30	540.87
5. Interest	0.13	0.15	0.70	0.64	0.70
6. Exceptional items	Nil	Nil	Nil	Nil	Nil
7. Profit/ (Loss) from Ordinary activities before tax (3) - (4+5+6)	3.04	14.08	2.30	60.94	54.72
8. Tax Expense (Including Deferred Tax)	(0.54)	4.54	0.00	19.36	16.99
9. Net Profit/ (Loss) from Ordinary activities after Tax (7-8)	3.58	9.54	2.30	41.58	37.74
10. Extraorindary Items	Nil	Nil	Nil	Nil	Nil
11. Net Profit/ (Loss) for the period (9-10)	3.58	9.54	2.30	41.58	37.74
12. Paid-up Equity Share Capital (Face Value of Rs.10/- each)	810.00	810.00	810.00	810.00	810.00
13. Reserves excluding revaluation reserves as per balance sheet of previous accounting year	293.26	293.26	134.02	293.26	134.02
14. Earnings Per Share (EPS)					
a. Basic and diluted EPS before extraordinary items for the period, for the year to data and for the previous year (not to be annualised)	0.05*	0.14	0.03*	0.60	0.55
15. Public Share Holding					
- Number of Shares	3166200	3366200	3366200	3166200	3366200
- Percentage of shareholding	39.09%	41.56%	41.56%	39.09%	41.56%
16. Promoters and promoter group shareholding					
a. Pledged / encumbered					
- No of Equity Shares	Nil	Nil	Nil	Nil	Nil
- Percentage of Shares (of the shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil	Nil
- Percentage of Shares (of the total share capital of the company)	Nil	Nil	Nil	Nil	Nil
a. Non encumbered					
- No of Equity Shares	4933800	4733800	4733800	4933800	4733800
- Percentage of Shares (of the shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%
- Percentage of Shares (of the total share capital of the company)	60.91%	58.44%	58.44%	60.91%	58.44%

* Weighted Average Number of Equity Shares considered



Trimurthi Drugs & Pharmaceuticals Ltd.

4-4-231/1/2 ABC, Inder Bagh, Sultan Bazar,
Hyderabad - 500 095, A.P., India

T: 040 2475 7370

W: www.trimurthigroup.com

TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED
AUDITED QUARTERLY RESULTS FOR THE QUARTER ENDED MARCH, 2014



TRIMURTHI
GROUP

Segment Reporting

Particulars	Quarters ended			Year ended	Year ended
	31/03/2014	31/12/2013	31/03/2013	31/03/2014	31/03/2013
	Audited	Unaudited	Audited	Audited	Audited
1. Segment Revenue					
a. Pharma Business	133.27	113.01	106.63	486.39	525.25
b. Financial Services	19.83	23.79	18.81	89.48	70.75
c. Investments	0.00	0.01	0.00	0.01	50.80
d. Trading in Shares	0.00	0.00	0.00	0.00	0.00
Total	153.10	136.81	125.44	575.88	646.80
2. Segment Profits					
a. Pharma Business	(13.32)	(14.49)	(14.49)	(19.51)	(9.50)
b. Financial Services	16.36	16.79	16.79	80.44	63.93
c. Investment	0.00	0.00	0.00	0.01	0.29
d. Trading in Shares	0.00	0.00	0.00	0.00	0.00
Total	3.04	2.30	2.30	60.94	54.72
3. Capital Employed					
a. Pharma Business	392.88	380.76	299.55	392.88	380.76
b. Financial Services	681.82	664.88	409.82	681.82	664.88
c. Investments	31.50	2.00	50.54	31.50	2.00
d. Trading in Shares	0.00	Nil	0.00	0.00	Nil
Total	1106.20	1047.64	759.91	1106.20	1047.64

Notes:

1. The above results have been reviewed by Audit Committee and approved by the board of directors of the company at their meeting held on 24-05-2014.
2. During the Quarter under review the Company has acquired 2,95,000 Equity Shares of Rs. 10/- each of M/s Trimurthi Pharmaceuticals (India) Private Limited representing 59% of its Capital thereby making it as a Subsidiary.
3. The financial results for the quarter ended 31-03-2014 have been reviewed by the statutory auditors in pursuance of listing agreement.
4. (a) In segment reporting common assets that are used interchangeable not allocated to the individual segment above.
(b) Previous Period Figures have been regrouped wherever necessary.
5. Figures of last quarter ended on 31-03-2014 are the balancing figures between audited figures in respect of the full financial year ended on 31-03-2014 and the published year to date figures upto the third quarter ended on 31-12-2013 of the current financial year.
6. The status of investor grievances for the quarter ended 31/03/2014:
 - a. pending at the beginning - Nil
 - b. received - 1
 - c. settled - 1
 - d. pending at the end - Nil

Place : Hyderabad,
Date :



TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED
STANDALONE ASSETS AND LIABILITIES FOR THE HALF YEAR ENDED ON 31/03/2014

TRIMURTHI
GROUP

(Rupees in Lacs)

Particulars	As at 31/03/2014	As at 31/03/2013
A. EQUITY AND LIABILITIES		
1. Share Holders' Funds:		
(a) Share Capital	810.00	810.00
(b) Reserves and Surplus	334.84	293.26
(c) Money received against warrants	0.00	
Sub-Total Share Holders' Funds	1144.84	1103.26
2. Share Application pending for Allotment	-Nil-	-Nil-
3. Minority Interest*	-Nil-	-Nil-
4. Non Current Liabilities:		
(a) Long Term Borrowings	1.36	4.38
(b) Deferred Tax Liabilities (Net)	11.60	13.70
(c) Other Long Term Liabilities	-Nil-	-Nil-
(d) Long Term Provisions	-Nil-	-Nil-
Sub-Total Non Current Liabilities	12.96	18.08
5. Current Liabilities		
(a) Short Term Borrowings	-Nil-	-Nil-
(b) Trade Payables	4.51	2.20
(c) Other Current Liabilities	10.70	11.08
(d) Short Term Provisions	21.46	19.58
(e) Inter Division	-Nil-	-Nil-
Sub-Total Current Liabilities	36.67	32.86
TOTAL EQUITY & LIABILITIES	1194.47	1154.20
B. ASSETS		
1. Non-Current Assets:		
(a) Fixed Assets	117.15	121.82
(b) Non-Current Investments	31.50	2.00
(c) Deferred Tax Assets (Net)	-Nil-	-Nil-
(d) Long Term Loans and Advances	20.52	21.78
(e) Other Non-Current Assets	-Nil-	12.21
Sub-Total Non Current Assets	169.17	157.81
2. Current Assets:		
(a) Current Investments	-Nil-	-Nil-
(b) Inventories	32.21	33.28
(c) Trade Receivables	84.72	81.64
(d) Cash & Cash Equivalents	86.95	36.90
(e) Short Term Loans and Advances	806.09	822.74
(f) Other Current Liabilities	15.33	21.83
Sub-Total Current Assets	1025.30	996.39
TOTAL ASSETS	1194.47	1154.20

Trimurthi Drugs & Pharmaceuticals Ltd.

4-4-231/1/2 ABC, Inder Bagh, Sultan Bazar,
 Hyderabad - 500 095, A.P., India
 T: 040 2475 7370
 W: www.trimurthigroup.com



Date: 24-05-2014

To,
The Secretary,
The Bombay Stock
Exchange Limited
Floor 25, P.J. Towers,
Dalal Street,
Mumbai. - 400 001

The Manager (Listing
Department)
The Ahmedabad Stock
Exchange Ltd.,
Kamadhenu Complex,
Opp. Sahajanand College,
Panjarapole,
Ahmedabad

To,
The Manager (Listing
Department)
The Madras Stock
exchange,
Chennai

Sub : Outcome of the Board meeting.

The meeting of the Board of Directors of the company was held at 04:30 pm today. The out come of the meeting is under:

The Board has considered and approved the minutes of the previous board meeting.


Board has taken note of Disclosure of Interest made by the Directors.

The Board has considered and approved the Standalone and Consolidated Audited Financials for the Quarter and Year ended 31st March, 2014.

There being no other matter meeting of the board of directors concluded with the vote of thanks.

Thanking you

Yours truly,
for TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED.



ARVIND KUMAR BHANGADIA
Managing Director